NEW YORK (GenomeWeb News) – AstraZeneca and the Broad Institute today said they will collaborate on identifying new compounds that target bacterial and viral infections.

The alliance will employ Broad's expertise in bacterial genomics and biochemistry with its chemical library of 100,000 customized molecules known as Diversity-Oriented Synthesis compounds. The library is "designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets," the partners said in a joint statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.